Molecular Subtypes Drive Treatment Outcomes in Stage III Endometrial Cancer, Canadian Study Shows
核心洞察
A retrospective study reveals that patients with MSI-H (搜索), p53 abnormal, and NSMP molecular subtypes of stage III endometrial cancer (搜索) showed significant benefits from combined chemotherapy and radiation therapy post-surgery.
Patients with NSMP disease demonstrated superior outcomes with 80.8% 5-year overall survival rate, compared to 68.6% for MSI-H (搜索) and 56.2% for p53 abnormal subtypes.
Sequential postoperative radiotherapy significantly improved survival outcomes across all molecular subtypes, with notably better results when combined with chemotherapy versus single-modality treatment.
A comprehensive retrospective analysis of stage III endometrial cancer (搜索) patients in British Columbia (搜索), Canada, has revealed that molecular subtyping significantly influences treatment outcomes and survival rates, highlighting the importance of personalized therapeutic approaches.
The study, presented at the 2025 SGO Winter Meeting, examined patients diagnosed between 2017 and 2021, focusing on molecular subtypes including microsatellite instability-high (MSI-H (搜索)), p53 abnormal, and no specific molecular pattern (NSMP).
Treatment Response Across Molecular Subtypes
Patients with MSI-H (搜索) disease showed varying responses based on chemotherapy cycles. Those receiving 4-6 cycles achieved the best outcomes, with median overall survival (OS) not yet reached. The study demonstrated a clear correlation between treatment intensity and survival benefits, with patients receiving optimal chemotherapy dosing showing superior outcomes.
NSMP emerged as the most favorable subtype, with an impressive 80.8% 5-year OS rate and 86.6% disease-free survival (DFS) rate. In contrast, MSI-H (搜索) patients showed a 68.6% 5-year OS rate, while p53 abnormal cases demonstrated the lowest survival rates at 56.2%.
Impact of Combined Therapy
The research strongly supports the benefits of sequential postoperative radiotherapy across all molecular subtypes. Patients receiving both chemotherapy and radiation therapy showed significantly improved survival outcomes compared to those receiving single-modality treatment or no adjuvant therapy (P < .0001).
Median OS for patients receiving adjuvant radiation (n=89) was not yet reached, compared to 38.7 months for those who did not receive radiation therapy. The combination of chemotherapy and radiation therapy proved particularly effective, with superior DFS rates compared to either modality alone.
Prognostic Factors and Disease Staging
A multivariable analysis revealed that advanced disease staging significantly impacted survival outcomes. FIGO stage 3C patients showed worse survival compared to stage 3A (HR, 3.416; 95% CI, 1.076-10.848), while grade 3 disease demonstrated a trend toward poorer outcomes compared to grade 1 (HR, 2.779; 95% CI, 0.712-10.847).
Clinical Implications
These findings underscore the critical importance of molecular subtyping in endometrial cancer (搜索) management. As the most common gynecologic cancer among Canadian women, this research suggests that treatment protocols should be tailored based on molecular subtypes to optimize patient outcomes.
The study's results strongly support the integration of molecular classification into diagnostic and treatment protocols, moving away from traditional histomorphological classifications. This shift promises to improve prognostic accuracy and help clinicians make more informed treatment decisions for stage III endometrial cancer (搜索) patients.